IW-1973
Sponsors
Cyclerion Therapeutics, Akebia Therapeutics
Conditions
Diabetes Mellitus, Type 2HealthyHeart Failure With Preserved Ejection FractionHypertensionType 2 Diabetes Mellitus With Diabetic Nephropathy
Phase 1
Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
CompletedNCT02616861
Start: 2015-11-30End: 2016-06-30Updated: 2019-04-03
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
CompletedNCT03499106
Start: 2018-04-12End: 2018-07-06Updated: 2019-04-03
Phase 2
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
CompletedNCT02906579
Start: 2016-09-30End: 2017-03-17Updated: 2020-04-16
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
CompletedNCT03091920
Start: 2017-02-28End: 2017-08-03Updated: 2020-08-31
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
CompletedNCT03217591
Start: 2017-08-01End: 2019-08-20Updated: 2022-09-15
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
CompletedNCT03254485
Start: 2017-11-07End: 2019-08-19Updated: 2022-09-15